Cargando…

Target Validation in Drug Discovery.

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics.

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Metcalf, Brian W.
Otros Autores: Dillon, Susan
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Burlington : Elsevier, 2006.
Temas:
Acceso en línea:Texto completo

MARC

LEADER 00000cam a2200000Mu 4500
001 EBOOKCENTRAL_ocn437175624
003 OCoLC
005 20240329122006.0
006 m o d
007 cr mn|---|||||
008 090817s2006 vtu ob 001 0 eng d
040 |a MERUC  |b eng  |e pn  |c MERUC  |d YDXCP  |d IDEBK  |d OCLCQ  |d UKDOC  |d OCLCQ  |d STF  |d OCLCO  |d OCLCF  |d ZCU  |d OCLCQ  |d MERUC  |d OCLCQ  |d OCLCO  |d U3W  |d ICG  |d OCLCQ  |d TKN  |d DKC  |d AU@  |d OCLCQ  |d OCLCO  |d OCLCQ  |d OCLCO 
019 |a 171113825  |a 742300089  |a 814470596  |a 823137324 
020 |a 9780080465975  |q (electronic bk.) 
020 |a 0080465978  |q (electronic bk.) 
020 |a 1280707607 
020 |a 9781280707605 
020 |z 0123693934  |q (alk. paper) 
029 1 |a DEBBG  |b BV044122343 
035 |a (OCoLC)437175624  |z (OCoLC)171113825  |z (OCoLC)742300089  |z (OCoLC)814470596  |z (OCoLC)823137324 
050 4 |a RM301.63  |a RM301.63 .T36 2006eb 
072 7 |a TDCW  |2 bicssc 
082 0 4 |a 615.19  |a 615/.19 22 
049 |a UAMI 
100 1 |a Metcalf, Brian W. 
245 1 0 |a Target Validation in Drug Discovery. 
260 |a Burlington :  |b Elsevier,  |c 2006. 
300 |a 1 online resource (293 pages) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
505 0 |a Front Cover; Title Page; Copyright Page; Table of Contents; Preface; Contributors; Chapter 1 Generation of Transgenic Animals; Chapter 2 Target Validation in Chemogenomics; Chapter 3 Cetuximab (Erbitux®), An Anti-Epidermal Growth Factor Receptor Antibody for the Treatment of Metastatic Colorectal Cancer; Chapter 4 Monoclonal Antibody to HER-2 in Breast Cancer; Chapter 5 Validation of TNF as a Drug Target in Inflammatory Bowel Disease; Chapter 6 Anti-CCL-2/MCP-1: Directed Biologicals for Inflammatory and Malignant Diseases; Chapter 7 Targeting IL-12p40 for Immune-Mediated Disease. 
505 8 |a Chapter 8 The GPIIb/IIIa Antagonist Abciximab for Acute Percutaneous Coronary InterventionChapter 9 Epidermal Growth Factor Receptor (EGFR) Inhibitor for Oncology: Discovery and Development of Erlotinib; Chapter 10 Progress in Achieving Proof of Concept for p38 Kinase Inhibitors; Chapter 11 IKK-2/NF-kappa B-Dependent Transcription; Chapter 12 TNF Signaling Pathway Inhibitors for Inflammation-CCR2 Antagonists; Cha. 
520 |a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. 
588 0 |a Print version record. 
504 |a Includes bibliographical references and index. 
590 |a ProQuest Ebook Central  |b Ebook Central Academic Complete 
650 0 |a Drug development. 
650 0 |a Drugs  |x Testing. 
650 0 |a High throughput screening (Drug development) 
650 6 |a Médicaments  |x Développement. 
650 6 |a Médicaments  |x Essais cliniques. 
650 6 |a Criblage à haut débit (Développement des médicaments) 
650 7 |a Drug development  |2 fast 
650 7 |a Drugs  |x Testing  |2 fast 
650 7 |a High throughput screening (Drug development)  |2 fast 
700 1 |a Dillon, Susan. 
776 1 |z 9780123693938 
856 4 0 |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=282102  |z Texto completo 
938 |a 123Library  |b 123L  |n 44592 
938 |a ProQuest MyiLibrary Digital eBook Collection  |b IDEB  |n 70760 
938 |a YBP Library Services  |b YANK  |n 2585775 
994 |a 92  |b IZTAP